Glaxosmithkline | Des Atouts



Assets Changement Date
AbbVie USD 136.17B 1B 2025-03
Amgen USD 87.9B 1.47B 2025-06
AstraZeneca USD 112.42B 6.17B 2025-06
Aurora Cannabis CAD 866.52M 57.75M 2024-12
Bausch Health Companies USD 27.27B 845M 2025-06
Bristol-Myers Squibb USD 94.68B 2.25B 2025-06
Canopy Growth CAD 1.16B 68.13M 2024-12
Corcept Therapeutics USD 801.72M 44.73M 2025-06
Drreddys Laboratories INR 481.06B 15.1B 2024-12
Eli Lilly USD 100.92B 11.53B 2025-06
GlaxoSmithKline GBP 59.26B 1.45B 2025-06
Glaxosmithkline GBP 59.46B 1.41B 2024-12
J&J USD 193.67B 13.57B 2025-03
Merck USD 117.52B 2.4B 2025-06
Novartis USD 104.4B 4.45B 2025-06
Pacira USD 1.54B 49.41M 2025-06
Perrigo USD 10.09B 334.3M 2025-06
Pfizer USD 206.1B 1.93B 2025-06
Prestige Brands USD 3.43B 29.41M 2025-06
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 124.96B 6.93B 2025-06
Supernus Pharmaceuticals USD 1.38B 35.11M 2025-06
Takeda JPY 14T 243.81B 2025-06
Teva Pharmaceutical Industries USD 40.13B 1.72B 2025-06
Zoetis USD 14.48B 381M 2025-06


Glaxosmithkline Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.